ArticleJournal of substance abuse treatment2020
West Virginia's model of buprenorphine expansion: Preliminary results.
Article in Journal of substance abuse treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Addiction care outcomes between insured and state opioid response grant-funded patients in a Medicaid non-expansion state.Journal of substance use and addiction treatment · 2026Article
- Implementation challenges and opportunities in decentralized methadone service delivery.BMC health services research · 2025Article
- Implementation Challenges and Opportunities in Decentralized Methadone Service Delivery.Research square · 2025Article
- Implementation opportunities for optimizing retention on buprenorphine treatment for people with opioid use disorder in West Virginia.Drug and alcohol dependence · 2025Article
- Effectiveness of Washington State's hub and spoke model to improve opioid use disorder outcomes.Health affairs scholar · 2025Article
- Advancing access to substance use prevention for foster youth through digital innovation: an open trial of fostrspace with court appointed special advocate programs.BMC health services research · 2025Article
- Relationship of hub and treatment characteristics with client outcomes in the initial Washington State hub and spoke cohort.Journal of substance use and addiction treatment · 2025Observational
- Perspectives on APRN prescribing of medications for opioid use disorder: Key barriers remain.Journal of substance use and addiction treatment · 2024Article
- Understanding Regional Patterns of Overdose Deaths Related to Opioids and Psychostimulants.Substance use & misuse · 2024Observational
- Association of Loneliness and Mindfulness in Substance Use Treatment Retention.International journal of environmental research and public health · 2023Article
- Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids.JAMA health forum · 2023Article
- Assessing and Addressing the Determinants of Appalachian Population Health: A Scoping Review.Journal of Appalachian health · 2023Article
- Characterization of Unintentional Deaths Among Buprenorphine Users.Journal of studies on alcohol and drugs · 2023Article
- A Better Life: Factors that Help and Hinder Entry and Retention in MAT from the Perspective of People in Recovery.Journal of Appalachian health · 2023Article
- Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use.Drug and alcohol dependence reports · 2022Article
- Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia.Journal of substance abuse treatment · 2022Article
- Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.JAMA network open · 2021Article
- Financial sustainability of payment models for office-based opioid treatment in outpatient clinics.Addiction science & clinical practice · 2021Review
- Project ECHO Cancer Initiative: a Tool to Improve Care and Increase Capacity Along the Continuum of Cancer Care.Journal of cancer education : the official journal of the American Association for Cancer Education · 2021Article
- Longitudinal assessment of mental health and well-being in patients being treated with medications for opioid use disorder in primary care.Addictive behaviors reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
West Virginia (WV) is situated at the epicenter of the opioid epidemic with the highest rates of overdose deaths and some of the lowest rates of access to life saving evidence-based medication assisted treatment (MAT) for patients with opioid use disorder (OUD). WV used a modified hub-and-spoke model to build organizational capacity for facilities to use buprenorphine to treat patients with OUD and to provide ongoing case consultation. The purpose of this study is to 1) describe the group-base model of buprenorphine treatment and the model used to build organizational capacity, 2) to describe the preliminary results of buprenorphine expansion in WV and 3) to report preliminary data describing and comparing the characteristics of the patients served across five hubs. A single Coordinating Center uses video conferencing to train hubs and provide ongoing case consultation, as well as clinical support. Hubs were trained to deliver a buprenorphine treatment model that is multi-disciplinary and includes group-based medication management and psychosocial therapy. Five regional hubs independently treat patients and are leading MAT expansion in their local areas by training and mentoring spokes (n = 13). As a result of the WV STR funding, 14 health care facilities have started to use buprenorphine, 56 health professionals were trained and 196 patients with OUD have been treated. There were few sociodemographic characteristic differences across patients treated at the five hubs, while there were differences in self-reported alcohol and drug use in the 30 days prior to intake. Additional research is needed to determine whether the WV modified hub-and-spoke model resulted in statistically significant improvements in buprenorphine treatment capacity; there is a need to address MAT stigma and regulatory barriers in order to ensure the long-term sustainability of the buprenorphine expansion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.